Nahum Méndez-Sánchez

TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.

TL;DR: A review of recent concepts in OS, antioxidants and the molecular pathways involved in hepatic fibrosis highlights new molecular targets with therapeutic potential for more targeted and personalized control of this disease.

TL;DR: Aliment Pharmacol Ther 2011; 34: 509–518

TL;DR: A consensus is reached to endorse the proposal that the disease should be renamed as MAFLD and that the Disease should be diagnosed by the proposed simple and easily applicable criteria, and it is expected that this change in nosology will result in improvements in disease awareness and in advances in scientific, economic, public health, political, and regulatory aspects of the disease.

TL;DR: Non‐alcoholic fatty liver disease (NAFLD), the hepatic manifestation of MetS, is now the commonest liver disease worldwide and can evolve into cirrhosis in a subgroup of patients.